Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1352727

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1352727

Cancer Therapies

PUBLISHED:
PAGES: 915 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5450
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16350

Add to Cart

Description

Table of Contents

What`s New?

» Special discussions on the global economic climate and market sentiment

» Coverage on global competitiveness and key competitor percentage market shares

» Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial

» Online interactive peer-to-peer collaborative bespoke updates

» Access to our digital archives and MarketGlass™ research platform

» Complimentary updates for one year

» Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes

Economic Outlook

The global economic outlook is improving, and growth recovery, albeit on the lower side, is expected for this year and the next. The United States although witnessing slowing GDP growth in response to tight monetary and financial conditions, has nevertheless overcome the recession threat. Easing of headline inflation in Euro area is helping boost real incomes and is contributing to pick-up in economic activity. China is expected to see strong increases in GDP in the coming year as the pandemic threat recedes and the government sheds its zero-COVID policy. With optimistic GDP projections, India remains on-course to emerge into a US$6 trillion economy by 2030, surpassing Japan and Germany.

The upturn, however, remains fragile and a number of interlocking challenges continue to run in parallel, such as continued uncertainty around the war in Ukraine; slower than expected decline in global headline inflation; continuation of food and fuel inflation as a persistent economic problem for most developing countries; and still high retail inflation and its impact on consumer confidence and spending. Countries and their governments are showing signs of weathering these challenges, which helps lift market sentiments. As governments continue to combat inflation to get it down to more economically conformable levels by raising interest rates, new job creation will slowdown and impact economic activity. Stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced.

Although corporate investments can likely be held back by inflation worries and weaker demand, rise of new technologies will reverse partially this prevailing investment sentiment. Rise of generative AI; applied AI; industrializing machine learning; next-generation software development; Web3; cloud and edge computing; quantum technologies; electrification and renewables and climate technologies beyond electrification and renewables, will open up the global investment landscape. The technologies hold the potential to drive sizeable incremental growth and value to global GDP in the coming years. The short-term is expected to be a mixed bag of challenges and opportunities for both consumers and investors alike. There is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Cancer Therapies Market to Reach $335.9 Billion by 2030

The global market for Cancer Therapies estimated at US$171.6 Billion in the year 2022, is projected to reach a revised size of US$335.9 Billion by 2030, growing at a CAGR of 8.8% over the period 2022-2030. Chemotherapy, one of the segments analyzed in the report, is projected to record 8.1% CAGR and reach US$97 Billion by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at 9% CAGR for the next 8-year period.

The U.S. Market is Estimated at $67.6 Billion, While China is Forecast to Grow at 10.3% CAGR

The Cancer Therapies market in the U.S. is estimated at US$67.6 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$27.9 Billion by the year 2030 trailing a CAGR of 10.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.4% and 9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 10.1% CAGR.

Select Competitors (Total 80 Featured) -

  • Bristol-Myers Squibb Company
  • Astellas Pharma, Inc.
  • Bayer AG
  • Bavarian Nordic A/S
  • Bayer Corporation
  • BioLineRx Ltd.
  • Antigen Express, Inc.
  • Aptose Biosciences, Inc.
  • Biodesix, Inc.
  • Adastra Labs Holdings Limited
  • Bayer AG, Pharmaceuticals
  • Anchiano Therapeutics, Inc.
  • Adastra Pharmaceuticals, Inc.
  • APT Asia Pacific
  • Celgene Corporation
Show more
Product Code: MCP-1551

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Cancer Therapies: An Outlook
    • Chemotherapy & Targeted Therapy Lead the Global Cancer Therapies Market
    • By Cancer Type
    • USA Leads the Cancer Therapies Market
    • Biotherapies to Drive Growth
    • Rise in Cancer Incidence & Access to Modern Therapeutics Foster Growth
    • Total Number of New Cancer Cases by Type: 2018
    • Total Number of Cancer Deaths by Type: 2018
    • Cancer Incidence by Region: 2018
    • Cancer Mortality by Region: 2018
    • Age-Standardized Incidence and Mortality Rates of All Cancers (per 100000 Population) by Region: 2018
    • Cancer Research Spending Continues to Witness Growth
    • Number of FDA-Approved Cancer Drugs: 2010-2018
    • Select Cancer Drug Approvals in 2019
    • Select Cancer Drug Approvals in 2018
    • Cancer Drug Pipeline to Change the Pharma Landscape
    • Increasing Share of Cancer Drugs as % Of Total Pharma Drug Pipeline: 2010-2019
    • Cancer Therapies - Global Key Competitors Percentage Market Share in 2023 (E)
    • Select Leading Cancer Drugs Worldwide by Sales: 2018
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)
  • 2. FOCUS ON SELECT PLAYERS
    • AbbVie, Inc. (USA)
    • Amgen, Inc. (USA)
    • Astellas Pharma, Inc. (Japan)
    • AstraZeneca Plc. (UK)
    • Bayer AG (Germany)
    • Bristol-Myers Squibb Company (USA)
    • Select Late Stage Compounds in Bristol-Myers Squibb Company's Oncology Pipeline (As of 2019)
    • Celgene Corporation (USA)
    • Eli Lilly and Company (USA)
    • F. Hoffmann-La Roche Ltd. (Switzerland)
    • Glaxosmithkline Plc (UK)
    • Johnson & Johnson Services, Inc. (USA)
    • Merck KGaA (Germany)
    • Novartis AG (Switzerland)
    • Pfizer, Inc. (USA)
    • Takeda Pharmaceutical Company Limited (Japan)
  • 3. MARKET TRENDS & DRIVERS
    • Industry Focuses on New Approaches to Treat Cancer
    • Recent Advancements in Cancer Drug Discovery
    • A New Immunotherapy Technique that Improves Efficacy and Safety of Cancer Treatment Developed by an Institute for Molecular Engineering Research Team
    • Lymphoma Therapy Developed by BeiGene Secures US FDA Approval
    • New Linker Technology for Enhancing Stability of ADCs
    • Personalized Medicine Gains Importance
    • Companion Diagnostics Accelerate Role of Personalized Medicine in Cancer Care
    • North American Companion Diagnostics Market (2019)
    • European Companion Diagnostics Market by Disease Area (2019)
    • Innovations in Cancer Drug Delivery: Key Factor in Product Differentiation
    • Peptoid-based Nanotubes Allow Precise, Targeted Delivery of Cancer Drugs
    • Combination Therapy: A Double Whammy Success
    • Patent Expiries of Branded Drugs to Trigger Generic Competition
    • Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe
    • Gene Therapy based Approaches Present Potential Weapon for Battle against Cancer
    • Development of Novel Drug Candidates and Potential Therapies
    • Non-Viral Gene Therapy to Expedite Cancer Research and Introduction of New Therapies
    • Rise in Patient Assistance Programs (PAPs)
    • Top Financial Concerns for Cancer Patients: Ranked In Order of Influence
    • Oral Oncolytic Abandonment Rate (in %) by Patient Out-of-Pocket Expenses
    • Growth Drivers and Restraints
    • Demographics & Lifestyles Raise the Risk of Cancer
    • Percentage Breakdown of New Cases for All Cancers by Gender (2019)
    • Percentage Breakdown of New Cases for Colon and Rectum Cancers by Gender (2019)
    • Percentage Breakdown of New Cases for Lung & Bronchus Cancers by Gender (2019)
    • Unmet Needs Leave Scope for Further Research and Development
    • Low Entry Barriers in Cancer Research Encourages Breakthrough Developments
    • Increasing Investments by National Health Authorities
    • NCI Funding for Cancer Research (2002, 2008, 2014 and 2020)
    • Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth
    • Molecular Imaging of Cancer: Critical in Improving Patient Outcomes
    • Innovations, Improvements, and Approvals Propel Growth
    • Select Cancer Drug Approvals (2018 & 2019)
    • Emerging Challenges in Cancer Drug Development
    • Drug Failures Deter Prospects of New Therapies
    • High Prices of Targeted Therapies Act as a Speed Breaker
    • Estimated Average Monthly Cost of Select Leading Cancer Drugs in the US as of 2016
    • Cancer Drug Approval Processes Need to Become More Flexible for Encouraging Innovation
    • Limited Tumor Specificity and Toxicity
    • Complicated Treatment Protocols: A Major Stumbling Block in Patient Compliance
    • Reduced Smoking
    • Global Cigarette Consumption Per Capita by Select Countries for 1970 and 2018
    • Reimbursement Coverage Remains a Major Challenge
    • Increase in Multidrug Resistance
    • Stringent Regulations Delay Market Approval
    • Challenges Encountered in Clinical Trials
    • Overview of Cancer Therapy Segments
    • Immunotherapy: A Promising Segment
    • Global Cancer Immunotherapy Market by Therapy Type (in %) for 2019
    • Monoclonal Antibodies for Cancer Treatment
    • Monoclonal Antibodies in Late-Stage Clinical Trials for Cancer Treatment
    • Vaccines: A Promising Future Area of Cancer Therapeutics
    • Approved Therapeutic Cancer Vaccines Worldwide
    • CAR-T Therapy: An Innovative Therapy Focused on Engineering of Patients' Immune Cells for Cancer Treatment
    • UK Researchers New Approach Holds Potential to Boost Immunotherapies
    • Targeted Therapy: An Overview
    • Types of Targeted Therapy
    • Chemotherapy: An Overview
    • Types of Chemotherapy
    • Risks Associated with Chemotherapy
    • Hormone Therapy
    • Drug Classes in Hormone Therapy
    • CANCER TYPES, APPROVED AND PIPELINE DRUGS
    • Prostate Cancer
    • Global Sales of Leading Prostate Cancer Drugs in US$ Million: 2018
    • Select General Risk Factors and their Relative Risk Rate in Prostate Cancer
    • Select FDA Approved Drugs for Palliative Treatment of Advanced Prostate Cancer
    • Select Drugs that Received Approval for Castration-Resistant Prostate Cancer (CRPC)
    • Prostate Cancer Phase IV Completed Clinical Trials with Results
    • Lung Cancer
    • Age-Standardized Lung Cancer Rates for Select Countries
    • Age-Standardized Lung Cancer Rates in Men for Select Countries
    • Age-Standardized Lung Cancer Rates in Women for Select Countries
    • Select FDA-Approved Non-Small Cell Lung Cancer Drugs
    • Select Phase IV Completed Clinical Trials with Results: As of Dec, 2019
    • Select Phase III Completed Clinical Trials with Results: As of December 30, 2019
    • Breast Cancer
    • Select FDA Approved Breast Cancer Drugs
    • Breast Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019
    • Breast Cancer Select Phase III Completed Clinical Trials with Results: As of Dec 30, 2019
    • Renal Cancer
    • Select FDA-Approved Renal Cell Carcinoma Drugs
    • Cervical Cancer
    • Colorectal Cancer
    • Select FDA-Approved Colorectal Cancer Drugs
    • Skin Cancer
    • Pancreatic Cancer
    • Non-Hodgkin's Lymphoma
    • Leukemia
    • Standard Approved Mode of Therapy for AML by Age Group
    • Blood Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019
    • Blood Cancer Phase III Completed Clinical Trials with Results: As of Dec 30, 2019
    • Bladder Cancer
    • Endometrial Cancer
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Cancer Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Cancer Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 15: World 16-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 18: World 16-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 21: World 16-Year Perspective for Blood Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 24: World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 27: World 16-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Gastrointestinal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Gastrointestinal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 30: World 16-Year Perspective for Gastrointestinal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Gynecologic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Gynecologic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 33: World 16-Year Perspective for Gynecologic Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 36: World 16-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 37: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 38: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 39: World 16-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 40: World Cancer Therapies Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • Market Overview
    • Rising Cancer Cases Spur Growth in Cancer Therapies Market
    • Estimated Number of New Cancer Cases and Deaths in the US (2019)
    • Number of Cancer Drugs in Development for the Years 2006, 2009, 2012, 2015 and 2018
    • Number of FDA-Approved Oncology Drugs in the US (2010-2018)
    • Cancer Drugs as % of Drug Pipeline in the US for the Period 2010-2019
    • Patient Assistance Programs Alleviate Cost Burden of Patients to Some Extent
    • Personalized Medicine Gathers Momentum for Cancer Treatment in the US
    • A Surging US Prostate Cancer Therapeutics Market
    • Medicaid Reimbursement Rates for Cancer Treatment with Radiation Indicate Notable Disparity among States
    • Oncology Care Model to Improve Quality and Reduce Financial Toxicity of Cancer Care
    • CMS Hikes Reimbursement Rate for CAR-T Therapy
    • Market Analytics
    • TABLE 41: USA Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • CANADA
    • Number of New Cancer Cases in Canada: 2019
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • JAPAN
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • CHINA
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • Cancer Therapies Market: Overview
    • Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018
    • Chinese Drug Makers Look to Strengthen Domestic Presence with Low-cost Products
    • TABLE 59: China Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 61: China 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 64: China 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • EUROPE
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • Rising Cancer Incidence and New Drug Development Augur Well for European Cancer Therapies Market
    • Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018
    • Number of New Cancer Cases Diagnosed (in Thousands) in the UK: 2018
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Cancer Therapies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Cancer Therapies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • FRANCE
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 76: France 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 79: France 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • GERMANY
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 82: Germany 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 85: Germany 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Italy Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 88: Italy 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 89: Italy Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Italy Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 91: Italy 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 92: UK Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: UK Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 94: UK 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 95: UK Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: UK Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 97: UK 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • SPAIN
    • TABLE 98: Spain Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Spain Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 100: Spain 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 101: Spain Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Spain Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 103: Spain 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • RUSSIA
    • TABLE 104: Russia Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Russia Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 106: Russia 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 107: Russia Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Russia Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 109: Russia 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 112: Rest of Europe 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 115: Rest of Europe 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • An Insight into Asia-Pacific Market for Cancer Therapies
    • Cancer Incidence in Asia: Number of New Cancer Cases (in Thousands) for 2019
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Therapies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Cancer Therapies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 118: Asia-Pacific 16-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 121: Asia-Pacific 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 124: Asia-Pacific 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • AUSTRALIA
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 125: Australia Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 126: Australia Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 127: Australia 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 128: Australia Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 129: Australia Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 130: Australia 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • INDIA
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 131: India Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 132: India Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 133: India 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 134: India Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 135: India Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 136: India 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • SOUTH KOREA
    • TABLE 137: South Korea Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 138: South Korea Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 139: South Korea 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 140: South Korea Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 141: South Korea Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 142: South Korea 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 143: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 144: Rest of Asia-Pacific Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 145: Rest of Asia-Pacific 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 146: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 147: Rest of Asia-Pacific Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 148: Rest of Asia-Pacific 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • LATIN AMERICA
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Cancer Therapies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Cancer Therapies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 151: Latin America 16-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2023 & 2030
    • TABLE 152: Latin America Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 153: Latin America Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 154: Latin America 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 155: Latin America Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 156: Latin America Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 157: Latin America 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • ARGENTINA
    • TABLE 158: Argentina Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 159: Argentina Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 160: Argentina 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 161: Argentina Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 162: Argentina Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 163: Argentina 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • BRAZIL
    • TABLE 164: Brazil Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 165: Brazil Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 166: Brazil 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 167: Brazil Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 168: Brazil Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 169: Brazil 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • MEXICO
    • TABLE 170: Mexico Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 171: Mexico Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 172: Mexico 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 173: Mexico Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 174: Mexico Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 175: Mexico 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 176: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 177: Rest of Latin America Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 178: Rest of Latin America 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 179: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 180: Rest of Latin America Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 181: Rest of Latin America 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • MIDDLE EAST
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Cancer Therapies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Cancer Therapies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 184: Middle East 16-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2023 & 2030
    • TABLE 185: Middle East Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 186: Middle East Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 187: Middle East 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 188: Middle East Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 189: Middle East Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 190: Middle East 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • IRAN
    • TABLE 191: Iran Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 192: Iran Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 193: Iran 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 194: Iran Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 195: Iran Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 196: Iran 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • ISRAEL
    • TABLE 197: Israel Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 198: Israel Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 199: Israel 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 200: Israel Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 201: Israel Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 202: Israel 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • SAUDI ARABIA
    • TABLE 203: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 204: Saudi Arabia Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 205: Saudi Arabia 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 206: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 207: Saudi Arabia Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 208: Saudi Arabia 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 209: UAE Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 210: UAE Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 211: UAE 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 212: UAE Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 213: UAE Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 214: UAE 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 215: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 216: Rest of Middle East Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 217: Rest of Middle East 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 218: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 219: Rest of Middle East Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 220: Rest of Middle East 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030
  • AFRICA
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 221: Africa Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 222: Africa Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 223: Africa 16-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
    • TABLE 224: Africa Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 225: Africa Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 226: Africa 16-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Sales for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2014, 2023 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!